Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3556483 | 1.00 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL497818 | 1.00 | SIGMAR1 (0.55) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL7827035 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL29221566 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| Hydrochloric Acid SCHEMBL1026469 | 0.98 | SIGMAR1 (0.53) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL28499340 | 0.90 | ACP3 (0.51) | SIGMAR1MEN1KMT2AMAPTPOLB | |
| SCHEMBL17441374 | 0.89 | ALDH1A1 (0.56) | SIGMAR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL1997227 | 0.89 | ALDH1A1 (0.56) | SIGMAR1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL24555089 | 0.88 | LTA4H (0.57) | MEN1KMT2ATSHRMEP1BLTA4H | |
| Serine SCHEMBL28178645 | 0.87 | ALPI (0.49) | SIGMAR1MEN1KMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | claimed |
| EP-3994238-B1 | LUBRICATING COMPOSITIONS CONTAINING BASIC ASHLESS ADDITIVES | LUBRIZOL CORP (US) | 2024-03-13 | — | — | EP | claimed |
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | claimed |
| CN-110669742-A | Method for improving laccase degrading activity of organophosphorus pesticide | 孙芳 | 2020-01-10 | — | — | CN | claimed |
| EP-2531487-A1 | ARYL BENZYLAMINE COMPOUNDS | Novartis AG (CH) | 2012-12-12 | — | — | EP | claimed |
| WO-2011095452-A1 | ARYL BENZYLAMINE COMPOUNDS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | claimed |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. | 2010-02-18 | — | — | US | claimed |
| WO-2007030706-A1 | FRAGMENTS OF THE GLUCAGON-LIKE PEPTIDE-I AND USES THEREOF | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2007-03-15 | — | — | WO | claimed |
| WO-2025122024-A1 | INJECTABLE COMPOSITIONS FOR THE POSTOPERATIVE TREATMENT OF MALIGNANT BRAIN TUMOURS | Общество с ограниченной ответственностью "Нейролайт Технолоджи" | 2025-06-12 | — | — | WO | disclosed |
| CN-118239879-A | Method for preparing 3-substituted oxindole, dihydroisoindigo and tetra-substituted ethane based on primary amine and application of primary amine | 泰山学院 | 2024-06-25 | — | — | CN | disclosed |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | NuCana plc (GB) | 2024-03-12 | — | — | US | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | NuCana plc (GB) | 2023-06-01 | — | — | US | disclosed |
| CN-115746073-A | Diastereoselective synthesis of phosphate derivatives and gemcitabine prodrug NUC-1031 | 努卡那有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-4837204-A | RENIN INHIBITORS; HYPOTENSIVE AGENTS | ABBOTT LABORATORIES (US) | 1989-06-06 | — | — | US | disclosed |
| EP-0307837-A2 | Renin-inhibiting peptidyl heterocycles | ABBOTT LABORATORIES (US) | 1989-03-22 | — | — | EP | disclosed |
| EP-0230266-A2 | Functionalized peptidyl aminodiols and -triols | ABBOTT LABORATORIES (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4069385-A | FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
| US-4032567-A | TRIIODOISOPHTHALIC ACID MONOAMINO ACID AMIDES, PROCESS FOR THE PREPARATION THEREOF, AND USE THEREOF AS X-RAY CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-06-28 | — | — | US | disclosed |
| US-3953501-A | X-RAY CONTRAST AGENTS | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165886-A1 | PHOSPHORAMIDATE DERIVATIVES OF 5 - FLUORO - 2' - DEOXYURIDINE FOR USE IN THE TREATMENT OF CANCER | SLC29A2, SLC29A1, TYMP | SIGMAR1 4218/4885MEN1 2045/4885KMT2A 2204/4885 |
| US-11925658-B2 | Phosphoramidate derivatives of 5-fluoro-2′—deoxyuridine for use in the treatment of cancer | SLC29A2, SLC29A1, TYMP | SIGMAR1 4272/4885MEN1 1958/4885KMT2A 2029/4885 |
| US-20100041612-A1 | Fragments of the Glucagon-Like Peptide-1 and Uses Thereof | GLP1R, IAPP, GIPR | SIGMAR1 3628/4885MEN1 641/4885KMT2A 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.